4. Reference
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.

5. References
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.
Levine BL, Miskin J, Wonnacott K, et al. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2016;4:

6. References
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.
Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.

7. Reference
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.

8. Reference
Creedon H, Byron A, Main J, et al. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer. Biochem Soc Trans. 2014;42(4):

9. References
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.
NCI Cancer Dictionary. ADCC. Accessed March 31, 2019.

11. References
National Institutes of Health. NCI dictionary of cancer terms. Accessed March 31, 2019.
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.
Ferris RL, Jaffee EM, Ferrone S. Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape. J Clin Oncol. 2010; 28(28):
National Institutes of Health. NCI dictionary of cancer terms. Accessed April 29, 2019.

12. Reference
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.

13. Reference
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.

14. References
Abbas AK, Lichtman AH. Basic Immunology: Functions and Disorders of the Immune System. Philadelphia, PA: Saunders/Elsevier, 2009.
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.

15. Reference
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.

16. Reference
Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7-19.

17. References
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.
Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7-19.
Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015;7(2):

18. References
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.
National Institutes of Health. NCI dictionary of cancer terms. Accessed March 31, 2019.

19. References
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.
NCI Cancer Dictionary. ADCC. Accessed March 31, 2019.

21. References
Vogelpoel LT, Baeten DL, de Jong EC, et al. Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol. 2015;6:79.
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.

22. Reference
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.

23. Reference
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.

25. References
Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26(11):
Vogelpoel LT, Baeten DL, de Jong EC, et al. Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol. 2015;6:79.

26. References
Brodin P, Jorjic V, Gao T, et al. Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences. Cell. 2015;160:37-47.
Muntasell A, Cabo M, Servitja S, et al. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Front Immunol. 2017;8:1544.
Murano E, Comaro E, Ralamini R et al. Improved Natural Killer cell activity and retained anti‑tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2‑positive breast cancer patients undergoing neoadjuvant chemotherapy. J Transl Med. 2015;13:204

27. References
Nordstrom JL, Gorlatov S, Zhang W, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):R123.
Ferris RL, Jaffee EM, Ferrone S. Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape. J Clin Oncol. 2010; 28(28):

28. References
Creedon H, Byron A, Main J, et al. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer. Biochem Soc Trans. 2014;42(4):
Punt J, et al. Kuby Immunology. 8th ed. New York, NY: W.H. Freeman and Company; 2019.
Vogelpoel LT, Baeten DL, de Jong EC, et al. Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol. 2015;6:79.
Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26(11):
Muntasell A, Cabo M, Servitja S, et al. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Front Immunol. 2017;8:1544.